Vision 2030 Roadmap​

At EverythingALS, our mantra of “care to cure” is encapsulated in our Vision 2030 plan. Our mission transcends the conventional non-profit model, adopting a dynamic, for-profit mindset focused on achieving a singular, transformative goal: the eradication of ALS by the year 2030. This target year is not just a deadline, but a milestone driven intention, marking the moment we aim to render our services obsolete in a world liberated from ALS.

Vision 2030 Roadmap to a Cure​

2024: The foundational year. ​

We’ll launch our initiatives, secure funding, expand our ecosystem, and kickstart pivotal research projects.

2025: The year of expansion. ​

Our focus will be on enhancing our funding streams, completing the development of our core ecosystem, and taking our research efforts to the global stage.​

2026: The year of consolidation. ​

We’ll aim to solidify our capital base, advance ongoing research, and establish a ‘fail fast’ approach to clinical testing.​

2027: The year of clinical trials.

​ With a financial foundation robust enough to support us through 2030, we’ll initiate clinical trials targeting 1-3 agents that have a high probability of success.​

2028: The year of acceleration. ​

Our objectives include fast-tracking clinical trials for various ALS subtypes and showcasing successes against genetic variations of the disease.​

2029: The year of rapid development.

We’ll focus on enhancing our drug development platform, achieving further successes against genetic forms of ALS, and advancing clinical trials for identified sporadic subtypes.​

2030: The culmination of our efforts.

A fully scalable rapid drug development platform, showcasing successes across all known sporadic subtypes and genetic forms of ALS.​

Our approach is methodical, underpinned by a robust management system that integrates objectives, timelines, and measures to ensure transparency and accountability.

Our strategy is driven by a principle of focused intensity and overwhelming action, guided by strict research funding guidelines upheld by our Scientific Board. Our areas of FOCUS include:​


Prioritizing repair, regeneration, and understanding the subtypes and root causes of ALS.​


Concentrating on finding cures that not only eliminate the disease but also restore function, through rapid drug development.​


Addressing all forms of ALS, ensuring our efforts benefit every individual affected by the disease.​


Setting clear objectives, timelines, and measures to track progress and impact.​

Vision 2030 is more than just a timeline; it’s a commitment to turning the tide against ALS. By focusing our efforts, resources, and research, we’re not just dreaming of a world without ALS—we’re actively building the path to make it a reality.​

Our focus is on an emerging research category, repair and regeneration, and we will fund research using a disciplined approach in five areas...

Address the
root cause

Eliminate or reduce neuronal, glial and axonal dysfunction​

Discover novel

Repair or regenerate motor neurons, axons and glial​


Promote and accelerate repair and regeneration​


Return brain function and enhance quality of life​​

Pioneer new

Restore nerve-muscle connection and communication​

Our Research portfolio must follow these criteria

  • FOCUS, on repair and regeneration research (must fall into one or more of the five categories above)
  • FOCUS, on identifying subtypes and root causes
  • FOCUS, on a cure, including return of function and rapid drug development
  • FOCUS, on all forms of ALS